Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 1021189 dose-finding study in worsening heart failure with preserved ejection fraction
2013-002288-25Phase 2Completed
- Sponsor
- Bayer
- Start
- Sep 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vericiguat oral suspension in heart failure with preserved ejection fraction (HFpEF) and chronic heart failure (CHF) (5 arms), sponsored by Bayer. Primary endpoints: Change from baseline to week 12 in left atrial volume and Change in NT-proBNP at 12 weeks. Started Sep 2013; status: completed.
02
Drugs
vericiguat oral suspension
03
Conditions
heart failure with preserved ejection fraction (HFpEF)chronic heart failure (CHF)
Beyond the preview
Go deeper on 2013-002288-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002288-25.